BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 30, 2026
Home » BioWorld Stock Report For Public Biotechnology Companies

BioWorld Stock Report For Public Biotechnology Companies

March 12, 2007

Article reprints

To read more on related topics, click on one of the words below.

BioWorld MedTech
    • Related Articles

      BioWorld Stock Report For Public Biotechnology Companies

      BioWorld Stock Report For Public Biotechnology Companies

      BioWorld Stock Report For Public Biotechnology Companies

    Popular Stories

    • Today's news in brief

      BioWorld
      BioWorld briefs for Jan 30, 2025.
    • Today's news in brief

      BioWorld MedTech
      BioWorld MedTech briefs for Jan. 30, 2026.
    • Brain with stroke illustration

      Brain-derived tau in blood predicts stroke severity and outcome

      BioWorld Science

      Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

    • Centessa’s CNT-9982 shows promise for MDD

      BioWorld Science
      Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
    • Red and blue bispecific antibodies

      First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

      BioWorld Science
      Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
    • BioWorld
      • Today's news
      • Analysis and data insight
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Newco news
      • Opinion
      • Regulatory
      • Science
    • BioWorld MedTech
      • Today's news
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Newco news
      • Opinion
      • Regulatory
      • Science
    • BioWorld Asia
      • Today's news
      • Analysis and data insight
      • Australia
      • China
      • Clinical
      • Deals and M&A
      • Financings
      • Newco news
      • Regulatory
      • Science
    • BioWorld Science
      • Today's news
      • Biomarkers
      • Cancer
      • Conferences
      • Endocrine/Metabolic
      • Immune
      • Infection
      • Neurology/Psychiatric
      • NME Digest
      • Patents
    • More
      • About
      • Advertise with BioWorld
      • Archives
      • Article reprints and permissions
      • Contact us
      • Cookie policy
      • Copyright notice
      • Data methodology
      • Infographics: Dynamic digital data analysis
      • Index insights
      • Podcasts
      • Privacy policy
      • Share your news with BioWorld
      • Staff
      • Terms of use
      • Topic alerts
    Follow Us

    Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing